Atrial fibrillation and bisphosphonate therapy

Area of Science:

• Pharmacology
• Cardiology
• Bone Metabolism

Background:

• Bisphosphonates are primary osteoporosis treatments, reducing vertebral and nonvertebral fractures.
• Concerns exist regarding a potential bisphosphonate-atrial fibrillation (AF) association, highlighted by the HORIZON study.
• Conflicting results from subsequent studies necessitate further investigation into this potential link.

Purpose of the Study:

• To evaluate the potential association between bisphosphonate therapy and atrial fibrillation (AF).
• To explore potential mechanisms underlying any observed cardiac effects.
• To assess the overall risk-benefit profile of bisphosphonates in metabolic bone disease.

Main Methods:

• Review of clinical trial data, including the HORIZON study.
• Analysis of epidemiological studies investigating bisphosphonate use and AF incidence.
• Examination of preclinical data on bisphosphonate effects on cardiac electrophysiology and cellular mechanisms.

Main Results:

• Some studies indicate an increased risk of serious AF with specific bisphosphonates (e.g., zoledronic acid).
• No direct evidence currently supports acute or chronic effects of bisphosphonates on cardiac electrophysiology.
• Potential mechanisms involve altered electrolyte balance and proinflammatory, profibrotic, and antiangiogenic effects.

Conclusions:

• The association between bisphosphonates and AF is not definitively established, with conflicting study results.
• Identified AF risks have not translated to increased mortality or stroke risk.
• The established efficacy and positive risk-benefit balance of bisphosphonates for osteoporosis and metabolic bone diseases persist.